Gunter von Minckwitz Selected Research

Epirubicin (Ellence)

1/2019	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
1/2019	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
1/2018	Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
3/2016	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
10/2015	A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
7/2015	Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
6/2013	Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
1/2012	Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
11/2011	Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
9/2011	Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gunter von Minckwitz Research Topics

Disease

193	Breast Neoplasms (Breast Cancer) 10/2021 - 01/2002
91	Neoplasms (Cancer) 11/2021 - 01/2002
25	Pathologic Complete Response 11/2021 - 02/2008
13	Triple Negative Breast Neoplasms 11/2021 - 06/2014
9	Febrile Neutropenia 02/2015 - 03/2007
8	Carcinoma (Carcinomatosis) 10/2017 - 05/2002
7	Neoplasm Metastasis (Metastasis) 10/2019 - 01/2008
6	Neutropenia 01/2018 - 06/2010
5	Inflammatory Breast Neoplasms 11/2019 - 01/2010
5	Residual Neoplasm 01/2019 - 02/2013
4	Diarrhea 01/2019 - 04/2010
4	Infections 01/2018 - 11/2011
4	Disease Progression 03/2016 - 01/2005
3	Nausea 01/2020 - 03/2016
3	Vomiting 01/2020 - 03/2016
3	Hypertension (High Blood Pressure) 03/2015 - 01/2012
3	Hand-Foot Syndrome 10/2014 - 04/2010
3	Cardiotoxicity 10/2011 - 01/2008
2	Fatigue 01/2020 - 01/2006
2	Circulating Neoplastic Cells 09/2017 - 05/2010
2	Heart Failure 03/2016 - 10/2011
2	Noninfiltrating Intraductal Carcinoma (DCIS) 02/2016 - 04/2012
2	Proteinuria 03/2015 - 10/2014
2	Genetic Predisposition to Disease (Genetic Predisposition) 01/2015 - 01/2015
2	Amenorrhea 04/2014 - 06/2011
2	Male Breast Neoplasms (Male Breast Cancer) 08/2013 - 01/2013
2	Mucositis 01/2012 - 01/2006
1	Genomic Instability 11/2021

Drug/Important Bio-Agent (IBA)

36	Hormones (Hormone)IBA 10/2021 - 04/2005
36	taxaneIBA 10/2021 - 08/2004
35	AnthracyclinesIBA 07/2020 - 12/2002
31	Trastuzumab (Herceptin)FDA Link 01/2020 - 01/2008
28	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 10/2002
25	Docetaxel (Taxotere)FDA Link 01/2018 - 10/2002
18	human ERBB2 proteinIBA 01/2019 - 01/2009
18	Epirubicin (Ellence)FDA LinkGeneric 01/2019 - 12/2002
16	Biomarkers (Surrogate Marker)IBA 11/2019 - 01/2008
16	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 12/2002
15	Phenobarbital (Luminal)FDA Link 10/2019 - 11/2010
14	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 10/2002
11	Carboplatin (JM8)FDA LinkGeneric 11/2021 - 01/2011
11	Bevacizumab (Avastin)FDA Link 01/2019 - 01/2012
11	Capecitabine (Xeloda)FDA Link 10/2015 - 04/2008
10	Estrogen ReceptorsIBA 10/2021 - 02/2007
10	Tamoxifen FDA LinkGeneric 02/2016 - 10/2002
9	ErbB Receptors (EGF Receptor)IBA 10/2021 - 01/2005
8	Biological ProductsIBA 06/2017 - 02/2007
7	Taxoids (Taxanes)IBA 01/2015 - 12/2002
6	Formaldehyde (Formol)FDA Link 07/2020 - 01/2010
6	ParaffinIBA 07/2020 - 01/2010
6	Aromatase InhibitorsIBA 02/2016 - 12/2005
5	Pharmaceutical PreparationsIBA 01/2020 - 01/2005
5	Lapatinib (GW572016)FDA Link 01/2019 - 01/2008
5	130-nm albumin-bound paclitaxelIBA 01/2019 - 10/2015
5	Messenger RNA (mRNA)IBA 01/2018 - 02/2013
5	Proteins (Proteins, Gene)FDA Link 06/2017 - 11/2008
5	Goserelin (Zoladex)FDA Link 10/2011 - 08/2005
4	Fluorouracil (Carac)FDA LinkGeneric 10/2015 - 08/2003
4	Bendamustine Hydrochloride FDA Link 12/2011 - 01/2008
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2021 - 06/2011
3	Progesterone Receptors (Progesterone Receptor)IBA 09/2021 - 01/2009
3	neratinibIBA 11/2019 - 03/2016
3	Cytotoxins (Cytolysins)IBA 01/2019 - 03/2007
3	pertuzumabIBA 01/2019 - 07/2015
3	Tyrosine Kinase InhibitorsIBA 12/2017 - 01/2005
3	Anastrozole (Arimidex)FDA LinkGeneric 02/2016 - 07/2007
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2015 - 01/2012
3	Methotrexate (Mexate)FDA LinkGeneric 10/2015 - 11/2007
3	pegfilgrastim (Neulasta)FDA Link 02/2015 - 06/2010
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2006 - 09/2002
2	PlatinumIBA 11/2021 - 06/2014
2	veliparibIBA 11/2021 - 01/2018
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 07/2020 - 10/2014
2	Epidermal Growth Factor (EGF)IBA 07/2020 - 12/2012
2	Ado-Trastuzumab EmtansineIBA 01/2020 - 01/2019
2	liposomal doxorubicin (Doxil)FDA Link 01/2019 - 01/2006
2	SolventsIBA 01/2019 - 03/2016
2	Indicators and Reagents (Reagents)IBA 04/2017 - 12/2003
2	Letrozole (Femara)FDA LinkGeneric 03/2015 - 03/2008
2	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 02/2015 - 03/2013
2	Ibandronic Acid (Boniva)FDA Link 10/2013 - 10/2011
2	Diphosphonates (Bisphosphonates)IBA 10/2013 - 04/2010
2	sphingosine kinaseIBA 10/2013 - 11/2008
2	Vinorelbine (Navelbine)FDA LinkGeneric 08/2013 - 04/2008
2	Gonadotropin-Releasing Hormone (GnRH)FDA Link 06/2011 - 08/2005
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2009 - 07/2008
1	RNA (Ribonucleic Acid)IBA 11/2021
1	palbociclibIBA 10/2021

Therapy/Procedure

96	Neoadjuvant Therapy 11/2021 - 10/2002
71	Drug Therapy (Chemotherapy) 12/2019 - 12/2002
65	Therapeutics 09/2021 - 01/2002
13	Adjuvant Chemotherapy 11/2019 - 01/2008
7	Aftercare (After-Treatment) 11/2018 - 07/2007
6	Radiotherapy 11/2019 - 03/2010
5	Mastectomy (Mammectomy) 11/2019 - 01/2010
3	Combination Drug Therapy (Combination Chemotherapy) 01/2018 - 01/2010
3	Operative Surgical Procedures 01/2015 - 11/2006
3	Segmental Mastectomy (Lumpectomy) 10/2014 - 11/2006
2	Chemoprevention 10/2011 - 01/2007
2	Duration of Therapy 10/2011 - 01/2010